[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medication-related-osteonecrosis-of-the-jaw\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medication-related-osteonecrosis-of-the-jaw":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,70,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100644690","autologous-platelet-concentrates-on-the-healing-of-extraction-sockets-100644690",false,"NCT07673848","Autologous Platelet Concentrates on the Healing of Extraction Sockets","The Role of Autogenous Platelet Concentrates (APCs) in Post-extraction Early Wound Healing of High-risk Medication Related Osteonecrosis of the Jaw (MRONJ) Patients.","Eligibility criteria\n\nAll of the following criteria must be fulfilled for inclusion:\n\n* Patient must be willing to read and sign a copy of the Informed Consent Form\n* Males and females ≥ 25 years old;\n* Patients who are currently or previously treated with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications for the management of cancer;\n* Patients who are treated with antiresorptive therapy, bisphosphonates, for osteoporosis for more than 5 years;\n* Patients who have been treated with antiresorptive therapy, bisphosphonates, for osteoporosis for less than 5 years and being concurrently treated with a systemic glucocorticoid;\n* Patients who are treated with denosumab in the last nine months and being concurrently treated with a systemic glucocorticoid;\n* Patients who are on the high-risk category to develop MRONJ based on the SDCEP guidance;\n* Patients who require dental extractions (one per quadrant per patient) of premolar or molar teeth which are irrational to treat for any reason;\n* Patients with a history of MRONJ.\n\nThe following patients will be excluded:\n\n* Patients with MRONJ at the area of extraction;\n* Patients with history of radiotherapy in the area of treatment;\n* Patients with metastatic bone disease in the area of treatment;\n* Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing which can affect interpretation of study results);\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial;\n* Dental extractions in people who are systemically unwell and who require hospital admission;\n* Patients with poor glycaemic control (uncontrolled diabetes);\n* Current smokers or smokers who have quit less than 10 years ago (including e-cigarettes)","ALL","25 Years",{"count":19,"type":20},44,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study will evaluate the effect of A-PRF, a second-generation APC, on early wound healing in high-risk MRONJ patients following dental extractions, utilising advanced non-invasive methods to assess and associate molecular and blood flow changes during early healing. The early healing events of the post-extraction socket will also be characterised in terms of volumetric changes in relation to intra-oral thermographic changes, blood flow changes, in tandem with clinical measures of soft tissue healing and post-operative pain assessment. The early healing events will be analysed up to 15 days, and the final recall will be 180 days after extraction.",[26],"Medication-related Osteonecrosis of the Jaw","NOT_YET_RECRUITING","2026-06-24",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":20},"2026-06-01",{"date":35,"type":20},"2029-06-01",{"name":37,"class":38},"Queen Mary University of London","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100639753","bone-quality-evolution-in-medication-related-osteonecrosis-of-the-jaw-assessed-by-cbct-b-onj-evol-100639753","NCT07588269","Bone Quality Evolution in Medication-Related Osteonecrosis of the Jaw Assessed by CBCT (B-ONJ EVOL)","Evolution of Bone Quality in Medication-Related Osteonecrosis of the Jaw: A Retrospective Multicenter Study Using Cone Beam Computed Tomography (CBCT)","B-ONJ EVOL","Inclusion Criteria:\n\n* Adult patient aged 18 years or older\n* Diagnosis of medication-related osteonecrosis of the jaw (MRONJ), stage 0, 1, or 2\n* Available diagnostic CBCT and at least 2 follow-up cone beam computed tomography (CBCT) examinations\n* Able to understand the study information and not opposed to participation\n\nExclusion Criteria:\n\n* Other jaw bone disease\n* History of cervicofacial irradiation\n* Stage 3 medication-related osteonecrosis of the jaw\n* Fewer than 2 follow-up cone beam computed tomography (CBCT) examinations","18 Years",{"count":49,"type":20},25,"OBSERVATIONAL","Medication-related osteonecrosis of the jaw (MRONJ) is a known complication of antiresorptive therapies such as bisphosphonates and denosumab. It can lead to bone damage in the jaw, with variable clinical outcomes depending on disease stage and management.\n\nCone Beam Computed Tomography (CBCT) is currently recommended for diagnosis and follow-up of MRONJ. However, most studies rely on qualitative or descriptive imaging findings, and little is known about how bone quality evolves over time using quantitative imaging parameters.\n\nThis retrospective multicenter study aims to describe the evolution of bone quality in patients with MRONJ using CBCT imaging. Bone parameters such as bone mineral density and trabecular structure will be measured at diagnosis and during follow-up.\n\nThe study will help improve understanding of bone changes over time in MRONJ and may contribute to better assessment and management of the disease.",[26,53],"Osteonecrosis of the Jaw",[55,56,57,58,59,60],"Medication-related osteonecrosis of the jaw","Cone beam computed tomography","Bone mineral density","Bone morphometry","Trabecular bone","Antiresorptive agents","2026-05-11",{"date":63,"type":31},"2026-05-14",{"date":65,"type":20},"2027-01",{"date":67,"type":20},"2027-04",{"name":69,"class":38},"Nantes University Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100626409","comparing-implant-retention-versus-removal-for-mronj-at-implant-sites-100626409","NCT07435259","Comparing Implant Retention Versus Removal for MRONJ at Implant Sites","Implant Retention Versus Removal for MRONJ at Implant Sites: A Prospective Study","Inclusion Criteria:\n\n* Patients diagnosed with medication-related osteonecrosis of the jaw (MRONJ) (AAOMS stage 0, 1, or 2) who have been treated with antiresorptive agents (e.g., bisphosphonates or denosumab) and\u002For selective estrogen receptor modulators (SERMs).\n* Presence of an MRONJ lesion involving at least one dental implant at the affected site.\n* Radiographic peri-implant bone loss between ≥20% and \\\u003C60% of the implant length at the most severe area on baseline imaging.\n* No implant mobility.\n* Able and willing to provide written informed consent after receiving an adequate explanation of the study purpose and procedures.\n\nExclusion Criteria:\n\n* History of radiotherapy to the head and neck region.\n* Presence of metastatic disease or bone diseases such as multiple myeloma or Paget's disease of the jaw.\n* Current treatment with anti-angiogenic agents (e.g., bevacizumab, ranibizumab, lenalidomide, sunitinib) or immunomodulatory agents (e.g., methotrexate) for cancer therapy.\n* Uncontrolled systemic disease that may contraindicate surgery or impair healing (e.g., uncontrolled diabetes, recent chemotherapy, severe immunosuppression).\n* Refusal of treatment or follow-up, withdrawal of consent, or inability to comply with study procedures.\n* Peri-implant bone loss outside the predefined range (\\\u003C20% or ≥60%) on preoperative imaging or intraoperative assessment.","20 Years",{"count":79,"type":20},50,[23],"Medication-related osteonecrosis of the jaw (MRONJ) is a condition that can occur in patients who take medications such as antiresorptive drugs for osteoporosis and other bone-related systemic diseases. Although the overall risk is relatively low, the number of affected patients is increasing as the population ages and dental implants are increasingly used to restore chewing function. When MRONJ develops at an implant site, deciding whether to keep or remove the implant becomes a difficult clinical problem.\n\nCurrent treatment recommendations for MRONJ are mainly based on disease stage. However, in situations where only part of the bone around an implant is affected, and the entire implant surface is not involved, there are no clear, evidence-based criteria to guide the decision between implant retention and implant removal. Some clinicians recommend removing all implants associated with necrotic bone to reduce the risk of recurrence. Others attempt to preserve implants that appear less severely affected. Implant retention may carry a risk of delayed healing or recurrence, whereas implant removal may cause additional surgical trauma that could potentially worsen the condition. Therefore, more objective criteria are needed to support clinical decision-making.\n\nIn peri-implantitis, another disease affecting the tissues around implants, the amount of bone loss observed on radiographs is often used as a reference for treatment decisions. Traditionally, implant removal has been considered when bone loss reaches approximately 50-60% of the implant length. When bone loss is less extensive, treatment aimed at preserving the implant may be attempted. However, it is unknown whether a similar bone loss threshold applies to patients with implant-related MRONJ.\n\nThe purpose of this prospective study is to evaluate whether the extent of peri-implant bone loss-particularly within the range of 20% to 60% of the implant length-can serve as a practical reference for deciding whether to retain or remove an implant in patients with implant-related MRONJ. By comparing clinical outcomes between implant retention and implant removal within this range of bone loss, this study aims to determine whether a bone-loss-based criterion can support treatment decisions.\n\nThe primary outcome of the study is complete mucosal healing at 6 months after treatment. Additional outcomes, including radiographic changes assessed by cone-beam computed tomography (CBCT) and recurrence of MRONJ-related clinical signs, will also be evaluated during the 1-year follow-up period after treatment initiation. CBCT imaging will be performed at 6 and 12 months after treatment to assess bone changes over time. Approximately 50 patients will be enrolled in this single-center prospective study. The findings are expected to provide structured clinical data to guide implant management decisions in patients with implant-related MRONJ.",[83],"Medication Related Osteonecrosis of the Jaw",[85,86,87,88,89,90,91,92],"Implant-related MRONJ","Peri-implant MRONJ","Dental implant","Peri-implant bone loss","Implant retention","Implant removal","Osteoporosis","Antiresorptive therapy","2026-03-10",{"date":95,"type":31},"2026-03-12",{"date":97,"type":20},"2026-03",{"date":99,"type":20},"2028-06",{"name":101,"class":38},"Kyunghee University Dental Hospital",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100591721","mronj-and-polynucleotides-hyaluronic-acid-hydrogel-regenfast-100591721","NCT06984107","MRONJ and Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®)","Intra-operative Application of Polynucleotides-Hyaluronic Acid Hydrogel (Regenfast®) for the Surgical Treatment of Medication-related Osteonecrosis of the Jaws (MRONJ): a Pilot Study","REG-MRONJ-1","Inclusion criteria:\n\n* Patients older than 18 years\n* Provided informed consent\n* MRONJ stage 1 and stage 2 diagnosis, in accordance to SICMF-SIPMO classification\n* Need to undergo surgical treatment of MRONJ\n\nExclusion criteria:\n\n* Patients with history of head and neck radiotherapy\n* Neurological and psychiatric conditions\n* Pregnancy\n* MRONJ stage 3 diagnosis\n* Patients who will receive a re-treatment for MRONJ\n* Patients with general contraindication for oral surgery\n* Patients unable to attend the out-patients visits scheduled by the protocol",{"count":112,"type":20},10,[23],"Several circumstances or conditions, such as wound extension or disease, can affect the hard and soft tissue healing after surgical treatment of MRONJ. Supportive therapies are therefore needed to help tissues wound healing. The primary objective of this pilot clinical case series is to evaluate the post-operative wound healing in a group of patients undergoing surgical therapy for MRONJ with intraoperative application of a gel based on polynucleotides and hyaluronic acid (PN+HA) (Regenfast®)",[83],"2025-05-22",{"date":118,"type":31},"2025-05-29",{"date":120,"type":20},"2025-09-01",{"date":122,"type":20},"2027-03-01",{"name":124,"class":38},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]